<DOC>
	<DOCNO>NCT00189644</DOCNO>
	<brief_summary>The main objective randomize trial compare 6 FEC100 4 FEC100 + 4 Taxol patient resect node positive breast cancer . Main endpoint disease free survival . Secondary endpoint overall survival , time local recurrence , time distant metastasis , tolerance . A total 840 patient include trial .</brief_summary>
	<brief_title>6 FEC 100 Vs 4 FEC 100 Followed 4 Taxol N+ Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Histologically proven cancer breast , Mastectomy complete tumorectomy , Histologically proven homolateral , axillary lymph node involvement ( least 1 N+ ) Period surgery ( second operation case primarily incomplete resection ) start chemotherapy &lt; 2 month , Biological criterion ( first FEC cycle ) : Neutrophils &gt; 1.5 109 /L Platelets &gt; 100 109/L Hemoglobin &gt; 10 g/dl Creatininemia &lt; 120 mmol/1 Bilirubinemia &lt; 1.5 Upper normal value Female patient 18 year old Written sign informed consent Performance Status less equal 2 ( WHO scale , see Annex IV ) Prior chemotherapy radiotherapy , include neoadjuvant treatment cancer breast , Bilateral breast cancer history contralateral breast cancer Cardiac history : cardiac insufficiency ( LVEF &lt; 50 % ) coronary decompensation Pregnancy breastfeeding ( effective contraception mandatory case woman childbearing potential ) Inflammatory breast cancer Distant metastasis supraclavicular adenopathy Benign pathology history malignant pathology accompany life expectancy less two year Contraindication Anthracyclines , Cyclophosphamide , 5FU Taxol Psychiatric pathology Patient participate another trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>